C 1311

Drug Profile

C 1311

Alternative Names: C-1311; Imidacrine; Imidazoloacridine; NSC 645809; Symadex; Symadex Pathfinder; XLS-002

Latest Information Update: 10 Feb 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Bradford
  • Developer Antisoma
  • Class Aminoacridines; Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Lymphoid leukaemia; Multiple sclerosis; Rheumatoid arthritis; Solid tumours; Ulcerative colitis

Most Recent Events

  • 11 Jun 2008 Xanthus Pharmaceuticals has been acquired and merged into Antisoma
  • 03 Jun 2008 Final adverse events data from a phase I trial in patients with advanced solid tumours presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 03 Jun 2008 Efficacy data from a phase II trial in advanced breast cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top